<DOC>
	<DOCNO>NCT00816049</DOCNO>
	<brief_summary>The purpose study increase fraction patient , become MRD-negative consolidation non-HR ALL group individualize intensification 6MP-dosage day 30-85 .</brief_summary>
	<brief_title>ALL2008 Protocol Childhood Acute Lymphoblastic Leukemia ( ALL ) - 6MP Consolidation Therapy</brief_title>
	<detailed_description>20 % child ALL still fail cure . The ALL-2008 protocol treatment research protocol aim improve overall outcome Nordic child adolescents ALL comparison ALL-2000 protocol previous NOPHO protocol . The specific primary objective randomise study : To increase fraction patient , become MRD-negative consolidation non-HR ALL group individualise intensification 6MP-dosage day 30-85 . We additionally measure EFS toxicity secondary end point effect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Childhood ALL All mandatory biological data available6 Written inform consent obtain Mixed lineage ALL Pretreatment glucocorticosteroids antileukemic agent 1 week ALL predisposition syndromes Previous cancer Off protocol administration additional chemotherapy induction therapy Sexually active female use contraception TPMTdeficiency</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>child</keyword>
	<keyword>6-mercaptopurine</keyword>
	<keyword>minimal residual disease</keyword>
	<keyword>efficacy</keyword>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
</DOC>